Skip to main content
SpringerLink
Log in

Current status of prostate brachytherapy in Japan

  • Invited Review
  • Published:
Japanese Journal of Radiology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. Grimm P, Billiet I, Bostwick D, Dicker AP, Frank S, Immerzeel J, et al. Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group. BJU Int. 2012;109(Suppl 1):22–9.

    Article  Google Scholar 

  2. Lawton CA, Hunt D, Lee WR, Gomella L, Grignon D, Gillin M, et al. Long-term results of a phase II trial of ultrasound-guided radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate (RTOG98-05). Int J Radiat Oncol Biol Phys. 2011;81(1):1–7.

    Article  Google Scholar 

  3. Crook JM, Gomez-Iturriaga A, Wallace K, Ma C, Fung S, Alibhai S, et al. Comparison of health-related quality of life 5 years after SPIRIT: surgical prostatectomy versus interstitial radiation intervention trial. J Clin Oncol. 2011;29(4):362–8.

    Article  Google Scholar 

  4. Prestidge BR, Winter K, Sanda MG, Amin M, Bice WS, Michalski J, et al. Initial report of NRG oncology/RTOG 0232: a phase III study comparing combined external beam radiation and transperineal interstitial permanent brachytherapy with brachytherapy alone for selected patients with intermediate risk prostatic carcinoma. Int J Radiat Oncol Biol Phys. 2016;96(2):S4.

    Article  Google Scholar 

  5. Chin J, Rumble RB, Kollmeier M, Heath E, Efstathiou J, Dorff T, et al. Brachytherapy for patients with prostate cancer: American society of clinical oncology/cancer care Ontario joint guideline update. J Clin Oncol. 2017;35(15):1737–43.

    Article  Google Scholar 

  6. Morris WJ, Tyldesley S, Rodda S, Halperin R, Pai H, McKenzie M, et al. Androgen suppression combined with elective nodal and dose escalated radiation therapy (the ASCENDE-RT Trial): an analysis of survival endpoints for a randomized trial comparing a low-dose-rate brachytherapy boost to a dose-escalated external beam boost for high- and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2017;98(2):275–85.

    Article  Google Scholar 

  7. Rodda S, Tyldesley S, Morris WJ, Keyes M, Halperin R, Pai H, et al. ASCENDE-RT: an analysis of treatment-related morbidity for a randomized trial comparing a low-dose-rate brachytherapy boost with a dose-escalated external beam boost for high- and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2017;98(2):286–95.

    Article  Google Scholar 

  8. Saito S, Ito K, Yorozu A, Aoki M, Koga H, Satoh T, et al. Nationwide Japanese prostate cancer outcome study of permanent Iodine-125 seed implantation (J-POPS). Int J Clin Oncol. 2015;20(2):375–85.

    Article  Google Scholar 

  9. Ito K, Saito S, Yorozu A, Kojima S, Kikuchi T, Higashide S, J-POPS Investigators, et al. Nationwide Japanese prostate cancer outcome study of permanent Iodine-125 seed implantation (J-POPS): first analysis on survival. Int J Clin Oncol. 2018;23(6):1148–59.

    Article  Google Scholar 

  10. Katayama N, Nakamura K, Yorozu A, Kikuchi T, Fukushima M, Saito S, et al. Biochemical outcomes and predictive factors by risk group after permanent iodine-125 seed implantation: prospective cohort study in 2316 patients. Brachytherapy. 2019;18(5):574–82.

    Article  Google Scholar 

  11. Tanaka N, Yorozu A, Kikuchi T, Higashide S, Kojima S, Ohashi T, et al. Genitourinary toxicity after permanent iodine-125 seed implantation: the nationwide Japanese prostate cancer outcome study of permanent iodine-125 seed implantation (J-POPS). Brachytherapy. 2019;18(4):484–92.

    Article  Google Scholar 

  12. Katayama N, Yorozu A, Maruo S, Kojima S, Ohashi T, Tanaka N, et al. Predictive factors of rectal toxicity after permanent iodine-125 seed implantation: prospective cohort study in 2339 patients. Brachytherapy. 2016;15(6):736–45.

    Article  Google Scholar 

  13. Ohashi T, Yorozu A, Saito S, Tanaka N, Katayama N, Kojima S, et al. Urinary and rectal toxicity profiles after permanent iodine-125 implant brachytherapy in Japanese men: nationwide J-POPS multi-institutional prospective cohort study. Int J Radiat Oncol Biol Phys. 2015;93(1):141–9.

    Article  Google Scholar 

  14. Koga H, Naito S, Ishiyama H, Yorozu A, Saito S, Kojima S, J-POPS Study Group, et al. Patient-reported health-related quality of life up to three years after the treatment with permanent brachytherapy: outcome of the large-scale, prospective longitudinal study in Japanese-prostate cancer outcome study by permanent I-125 seed implantation (J-POPS). Brachytherapy. 2019;18(6):806–13.

    Article  Google Scholar 

  15. Okihara K, Yorozu A, Saito S, Tanaka N, Koga H, Higashide S, et al. Assessment of sexual function in Japanese men with prostate cancer undergoing permanent brachytherapy without androgen deprivation therapy: analysis from the Japanese prostate cancer outcome study of permanent iodine-125 Seed Implantation database. Int J Urol. 2017;24(7):518–24.

    Article  CAS  Google Scholar 

  16. Nakamura K, Ohga S, Yorozu A, Saito S, Kikuchi T, Dokiya T, et al. Institutional patient accrual volume and the treatment quality of I-125 prostate seed implantation in a Japanese nationwide prospective cohort study. Strahlenther Onkol. 2019;195(5):412–9.

    Article  Google Scholar 

  17. Nakano M, Yorozu A, Saito S, Sugawara A, Maruo S, Kojima S, et al. Seed migration after transperineal interstitial prostate brachytherapy by using loose seeds: Japanese prostate cancer outcome study of permanent iodine-125 seed implantation (J-POPS) multi-institutional cohort study. Radiat Oncol. 2015;10:228.

    Article  CAS  Google Scholar 

  18. Ishiyama H, Satoh T, Yorozu A, Saito S, Kataoka M, Hashine K, et al. Multi-institutional retrospective analysis of learning curves on dosimetry and operation time before and after introduction of intraoperatively built custom-linked seeds in prostate brachytherapy. J Radiat Res. 2016;57(1):68–74.

    Article  Google Scholar 

  19. Miki K, Kiba T, Sasaki H, Kido M, Aoki M, Takahashi H, et al. Transperineal prostate brachytherapy, using I-125 seed with or without adjuvant androgen deprivation, in patients with intermediate-risk prostate cancer: study protocol for a phase III, multicenter, randomized, controlled trial. BMC Cancer. 2010;10:572.

    Article  Google Scholar 

  20. Konaka H, Egawa S, Saito S, Yorozu A, Takahashi H, Miyakoda K, et al. Tri-Modality therapy with I-125 brachytherapy, external beam radiation therapy, and short- or long-term hormone therapy for high-risk localized prostate cancer (TRIP): study protocol for a phase III, multicenter, randomized, controlled trial. BMC Cancer. 2012;12:110.

    Article  CAS  Google Scholar 

  21. JASTRO, JUA, Japan Radiological Society. Guidelines for safety control of permanent implantation brachytherapy of prostate cancer, 6th edn. Tokyo: 2018. (in Japanese).

  22. Hanada T, Yorozu A, Shinya Y, Kuroiwa N, Ohashi T, Saito S, et al. Prospective study of direct radiation exposure measurements for family members living with patients with prostate (125)I seed implantation: evidence of radiation safety. Brachytherapy. 2016;15(4):412–9.

    Article  Google Scholar 

  23. Satoh T, Dokiya T, Yamanaka H, Saito S, Ishiyama H, Itami J, et al. Postmortem radiation safety and issues pertaining to permanent prostate seed implantation in Japan. Brachytherapy. 2015;14(2):136–41.

    Article  Google Scholar 

  24. Yoshioka Y, Nose T, Yoshida K, Inoue T, Yamazaki H, Tanaka E, et al. High-dose-rate interstitial brachytherapy as a monotherapy for localized prostate cancer: treatment description and preliminary results of a phase I/II clinical trial. Int J Radiat Oncol Biol Phys. 2000;48(3):675–81.

    Article  CAS  Google Scholar 

  25. Kee DLC, Gal J, Falk AT, Schiappa R, Chand ME, Gautier M, et al. Brachytherapy versus external beam radiotherapy boost for prostate cancer: systematic review with meta-analysis of randomized trials. Cancer Treat Rev. 2018;70:265–71.

    Article  Google Scholar 

  26. Hiratsuka J, Jo Y, Yoshida K, Nagase N, Fujisawa M, Imajo Y. Clinical results of combined treatment conformal high-dose-rate iridium-192 brachytherapy and external beam radiotherapy using staging lymphadenectomy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2004;59(3):684–90.

    Article  Google Scholar 

  27. Ishiyama H, Kamitani N, Kawamura H, Kato S, Aoki M, Kariya S, et al. Nationwide multi-institutional retrospective analysis of high-dose-rate brachytherapy combined with external beam radiotherapy for localized prostate cancer: an Asian Prostate HDR-BT Consortium. Brachytherapy. 2017;16(3):503–10.

    Article  Google Scholar 

  28. Yoshioka Y, Kotsuma T, Komiya A, Kariya S, Konishi K, Nonomura N, et al. Nationwide, multicenter, retrospective study on high-dose-rate brachytherapy as monotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2017;97(5):952–61.

    Article  Google Scholar 

  29. Mendez LC, Ravi A, Chung H, Tseng CL, Wronski M, Paudel M, et al. Pattern of relapse and dose received by the recurrent intraprostatic nodule in low- to intermediate-risk prostate cancer treated with single fraction 19 Gy high-dose-rate brachytherapy. Brachytherapy. 2018;17(2):291–7.

    Article  Google Scholar 

  30. Sutani S, Yorozu A, Toya K, Nishiyama T, Ozu C, Yagi Y, et al. Whole-gland salvage treatment for recurrent prostate cancer after initial definitive radiotherapy: a case series of (125)I brachytherapy and robot-assisted radical prostatectomy. J Contemp Brachytherapy. 2019;11(3):201–6.

    Article  Google Scholar 

  31. Kunogi H, Wakumoto Y, Yamaguchi N, Horie S, Sasai K. Focal partial salvage low-dose-rate brachytherapy for local recurrent prostate cancer after permanent prostate brachytherapy with a review of the literature. J Contemp Brachytherapy. 2016;8(3):165–72.

    Article  Google Scholar 

  32. Morita M, Fukagai T, Hirayama K, Yamatoya J, Noguchi T, Ogawa Y, et al. Placement of SpaceOAR hydrogel spacer for prostate cancer patients treated with iodine-125 low-dose-rate brachytherapy. Int J Urol. 2020;27(1):60–6.

    Article  CAS  Google Scholar 

  33. Martin JM, Handorf EA, Kutikov A, Uzzo RG, Bekelman JE, Horwitz EM, Smaldone MC. The rise and fall of prostate brachytherapy: use of brachytherapy for the treatment of localized prostate cancer in the national cancer data base. Cancer. 2014;120:2114–211.

    Article  Google Scholar 

Download references

Funding

The authors have received no grants.

Author information

Authors and Affiliations

  1. Department of Radiology, National Hospital Organization Tokyo Medical Center, 2-5-1, Higashigaoka, Meguro-ku, Tokyo, 152-8902, Japan

    Atsunori Yorozu

Authors
  1. Atsunori Yorozu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Atsunori Yorozu.

Ethics declarations

Conflict of interest

The author has no conflict of interest to disclosure with respect to this article.

Ethical statement

This article does not contain any studies with human participants or animals performed by any of the authors.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yorozu, A. Current status of prostate brachytherapy in Japan. Jpn J Radiol 38, 934–941 (2020). https://doi.org/10.1007/s11604-020-00993-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11604-020-00993-7

Search

Navigation